• our current focus

    Nanomaterials from the hybrid of organic and inorganic materials for the treatment of cancer

  • our strategy

    build significant value in our nanomaterial drug candidates that address unmet medical needs

  • The PDX mission

    We aspire to substantially improve health care using our nanotechnology platforms

  • about pdx

    about pdx

    PDX Pharmaceuticals is located on the 13th floor of the OHSU’s Center for Health and Healing in Portland, Oregon. The company utilizes state of the art equipment at the Biomedical Engineering Department, core facilities, and animal facilities at OHSU.

  • our science

    our science

    RNA Interference (RNAi). Recent advances in genetic sequencing are beginning to shed light on functionally redundant genes which drive cancer development. RNA interference circumvents the druggability issue associated with…

  • our product pipelines

    our product pipelines

    Our nanoparticle carrier platform is a hybrid of polymer coating and inorganic nanoparticle core, which takes full advantage of both materials to overcome siRNA delivery barriers such as short bl

WELCOME TO PDX PHARMACEUTICALS

PDX Pharmaceuticals focuses on developing functionalized nanomaterials into drugs. We aspire to substantially improve health care using our nanotechnology platforms. PDX Pharma was established in 2010, supported by the Biomedical Engineering Department of Oregon Health and Science University (OHSU) School of Medicine and The Oregon Nanoscience and Microtechnologies Institute (ONAMI). We develop novel nanomaterials from the hybrid of organic and inorganic materials as carriers for targeted delivery or co-delivery of therapeutics for the treatment of cancer (breast, lung, melanoma, and colorectal cancer). Our drug cargos are carefully selected based on strong scientific rationale and knowledge in precision medicine and patient care. Our nanoparticle platform is versatile; it can deliver oligonucleotides, chemotherapy, antibody, small molecule inhibitors, vaccines, and/or imaging agents.

The Company’s strategy is to build significant value in our nanomaterial drug candidates that address unmet medical need and have substantial commercial potential, secure intellectual property rights, and initiate early stage commercial development (e.g., pre-clinical and toxicity evaluations, as well as Phase I clinical trials by partnering with OHSU). Upon sufficient validation of our candidates, the Company intends to partner with one or more large pharmaceutical companies that have expertise in clinical trial execution, manufacturing, and marketing.

Our technology has been developed through support from NIH (NCI, NCATS, NIDDK, NIGMS, NIEHS, NIAID), ONAMI, OHSU, PNNL, and Foundations (Prospect Creek, Gordon Moore, Hillcrest, Women’s Health Circle of Giving).